New Radioactive Drug Production Rooms Opened at Hadassah Ein Kerem Campus
The new production rooms in Israel for the production and development of radioactive drugs, built at the Hadassah Ein Kerem campus with an investment of 13 million shekels, were inaugurated. The ceremony was attended by Hadassah CEO Prof. Zeev Rotstein, CEO of S.R.Y. Company, Avi Blashnikov, senior officials from the Israeli healthcare system, and representatives from the Israeli Society for Nuclear Medicine.
S.R.Y. (Specialized Medical Services) is a subsidiary of Hadassah Ein Kerem Hospital, specializing in the production and development of radioactive drug products. It is the only company in the country with clean rooms and cyclotron facilities (particle accelerators), which include eight automated modules for the synthesis of various types of particles (cyclotron products). The construction of these new production rooms took about four years and included clean rooms and advanced systems for producing radioactive drug products without human contact, meeting the highest standards of the Ministry of Health, as well as European and U.S. FDA regulations, ensuring maximum patient safety.
S.R.Y.’s products are supplied for PET scans at Hadassah Ein Kerem Hospital and a number of other hospitals across the country, including Assuta, Beilinson, Sheba, Ichilov, and Shaare Zedek.
The cyclotron facilities are located about four floors underground in rooms with concrete walls 2.5 meters thick, essential for maintaining environmental safety. Notably, S.R.Y. is the only company in Israel with two cyclotron facilities operating simultaneously, serving as backups in case one facility is under maintenance.
S.R.Y. CEO Prof. Il Mishani, a pioneer in the cyclotron field in Israel and a senior advisor to the International Atomic Energy Agency, said the new facility includes the most advanced production rooms built to the highest standards currently available in the country, meeting both European and U.S. (FDA) regulations, which represent the highest level of patient safety.
Prof. Zeev Rotstein praised Prof. Mishani’s work and emphasized that patient safety is one of the central issues that should be prioritized in modern medicine. He added that the new production facility would effectively support thousands of patients each year at Hadassah and other hospitals in need of radioactive drug products.
Avi Blashnikov, Chairman of S.R.Y.’s Board of Directors and former Chairman of Hadassah Hospitals, welcomed the recent decision by the Ministry of Health to advance stricter regulations for radioactive drugs in Israel. He expressed hope that there would be uncompromising enforcement regarding those who operate without regulation and fail to meet strict safety standards.
Dr. Tzvi Bar-Sever, Chairman of the Israeli Society for Nuclear Medicine, stated that the new production rooms of S.R.Y. are of the highest level and serve as an example of quality in terms of work procedures, optimization, and quality control.
Source article: כתבת מקור: https://www.kolhair.co.il/health/14061/
